© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > Remibrutinib
<< Back to March
BTK-selective covalent kinase inhibitor
Ph. I completed in HV, in Ph. II
SBDD from reversible BTK inhibitor and opt.
J. Med. Chem., Mar. 4, 2020
Novartis, Basel, CH
Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)
Unlock this content with a Premium membership to read it now.